linjc16/ctgov huggingface dataset:
Significance of Synbiotics on Inflammation and Proliferation of Colonic Mucosa

Study Overview
=================
Brief Summary
-----------------
There is a constant exchange between the gut epithelium and lumen, including microbial interplay. The aim of this study was to investigate dietary test products on inflammatory proliferation markers in the gut, and thereby if the products had positive effects in the gut as well as in other parts of the body. The hypothesis was that the test products would reduce the inflammatory and proliferation activity of the gut epithelium by fermentation of normal food products and by converting dietary phenolic compounds into anti-inflammatory substances.

Official Title
-----------------
Significance of Synbiotics on Inflammation and Proliferation of Colonic Mucosa

Conditions
-----------------
Inflammation

Intervention / Treatment
-----------------
* Dietary Supplement: Lactobacillus
* Dietary Supplement: Bifidobacterium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-80 years old, Able to understand oral and written information, Informed consent Exclusion Criteria: Ongoing immune suppressive treatment, incl. cortisone, Ongoing antibiotic treatment or antibiotic treatment ended within 4 weeks, History of inflammatory bowel disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Probiotics_Lactobacillus<br>Intervention (2 weeks) with a strain of Lactobacillus | Dietary Supplement: Lactobacillus<br>* Intervention (2 weeks) with a strain of Lactobacillus<br>* Other names: Lactobacillus plantarum;|
| Experimental: Probiotics_Bifidobacterium<br>Intervention (2 weeks) of daily supplementation of a probiotic strain of Bifidobacterium. | Dietary Supplement: Bifidobacterium<br>* Intervention (2 weeks) with a strain of Bifidobacterium<br>* Other names: Bifidobacterium infantis;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reactivity of rectal mucosa | to study the reactivity of rectal mucosa after a standardized inflammatory insult before and after treatment with probiotics | after 2 weeks intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| influence on immune system | to study the influence on systemic leukocytes and regulatory T cells | after 2 weeks intervention |
The Impact of Resistance Exercise Training On Metabolic Dysregulation in Obese Children.

Study Overview
=================
Brief Summary
-----------------
Impact of resistance training in prepubertal children with obesity focusing mostly in changes in body composition and markers of insulin resistance. Hypothesis is that this will show positive changes in this randomized controlled trial.

Detailed Description
-----------------
24 obese prepubertal obese children randomized to either resistance training program or usual care for 12 weeks. Baseline blood profiles and DEXA scans done before and after 12 weeks of training with the help of kinesiology graduates from Concordia University kinesiology department.

Official Title
-----------------
The Impact of Resistance Exercise Training On Metabolic Dysregulation in Obese Children.

Conditions
-----------------
Childhood Obesity, Body Composition, Resistance Training, Insulin Resistance

Intervention / Treatment
-----------------
* Behavioral: resistance training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between 8-12y Prepubertal Not on medications with known impact on weight loss Exclusion Criteria: Pubertal Uncontrolled thyroid condition Type 2 diabetes

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: RT<br>resistance training | Behavioral: resistance training<br>* 2 times a week resistance training<br>|
| No Intervention: Routine care<br>General counseling on increasing physical exercise | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in body composition as per DEXA scans |  | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in insulin resistance as per HOMA score |  | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Resistance, Training, Obesity, Children
The Efficacy and Safety of Montelukast Sodium in the Prevention of Bronchopulmonary Dysplasia

Study Overview
=================
Brief Summary
-----------------
This study is multicentered, prospective, randomized, opened, parallel, intervention study. The aim of this study is to evaluate the efficacy and safety of Montelukast sodium in the prevention of bronchopulmonary dysplasia (BPD) in preterm infant, below 32weeks gestational age. The investigators evaluate the first effectiveness through the morbidity and mortality of bronchopulmonary dysplasia. And then, the investigators evaluate the second effectiveness through the oxygen index, the usage of mechanical ventilator about taking medicine after 2 Weeks, Oxygen Utilization After 4 Weeks, Proinflammatory Cytokine through the bronchial lavage fluid.

Official Title
-----------------
The Efficacy and Safety of Montelukast Sodium in the Prevention of Bronchopulmonary Dysplasia

Conditions
-----------------
Premature Birth, Infant, Very Low Birth Weight, Bronchopulmonary Dysplasia

Intervention / Treatment
-----------------
* Drug: Montelukast


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Preterm infants born at less than 32 weeks Birth 14 days after, oxygen or artificial ventilation who are using patient more than 20cal/kg/d by enteral feeding written consent of the parents Exclusion Criteria: congenital anomaly cardiovascular collapse investigator's opinion

Ages Eligible for Study
-----------------
Minimum Age: 2 Weeks
Maximum Age: 10 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Montelukast<br>montelukast sodium dosage < 1000g : 0.5 mg/D QD 1000g 1500g : 1.0 mg/D QD 1500g 2000g : 1.5 mg/D QD > 2000g : 2mg/D QD medication period : to discharge or GA 36wks | Drug: Montelukast<br>* a leukotriene D4 receptor antagonist; sodium salt is the active compound; structure in first source<br>* Other names: Singulair;|
| No Intervention: Control<br>Standard treatment of BPD and preterm infants | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of moderate to severe BPD or mortality | At corrected gestational age 36 weeks, to compare the incidence of moderate to severe BPD or mortality | corrected gestational age | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oxygen Index. Use of mechanical ventilation, oxygen, systemic steroid. Weight gain, adverse event |  | 1, 2, 4 weeks since starting study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
montelukast, BPD, singulair, prematurity
Treatment of Patients With Skin Burns Using Keratinocytes and Skin Fibroblasts

Study Overview
=================
Brief Summary
-----------------
Treatment of patients with burns of the skin of the 2nd degree using: autologous keratinocytes and skin fibroblasts mixed with collagen gel 7% (tissue equivalent of the skin)

Detailed Description
-----------------
Treatment of patients with burns of the skin of the 2nd degree by applying a wound covering with layer-by-layer cultured autologous keratinocytes and fibroblasts in collagen gel

Official Title
-----------------
Treatment of Patients With Skin Burns Using Autologous Keratinocytes and Skin Fibroblasts

Conditions
-----------------
Burns

Intervention / Treatment
-----------------
* Biological: Fibroblasts and keratinocytes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: skin burns of the 2nd degree Exclusion Criteria: acute and chronic infectious diseases: HIV, viral hepatitis, tuberculosis mental disorders pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Fibroblasts and keratinocytes treated patients<br>Fibroblasts and keratinocytes treated patients | Biological: Fibroblasts and keratinocytes<br>* Autologous cultured fibroblasts and keratinocytes For PR: The name  fibroblasts and keratinocytes is exactly the name of the cell product registered by our ministry of health. There is no trade or international name.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of cured patients | Number of patients cured | 1 month | 
| Number of patients with treatment-related adverse events | Cell application related adverse events assessed by blood count, liver and function tests | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
burns, fibroblasts, keratinocytes
The Variation of Movement Related Cortical Potential, Cortico-cortical Inhibition, and Motor Evoked Potential in Intracerebral Implantation of Antologous Peripheral Blood Stem Cells(CD34)in Old Ischemic Stroke

Study Overview
=================
Brief Summary
-----------------
Stem cell theray in old stroke patients is a study to treat stroke patients approved before in our hospital. We recruit these patients who received stem cell therapy and completed the study. We adopted movement-related cortical potential,and cortico-cortical inhibition to assess the stroke patients with or without stem cell therapy. Further analyzing the correlation of the motor related cortical potential and cortico-cortical inhibition among them. We wanted to find out if there are changes in cortical excitability in subjects with chronic stroke after stem cell therapy.

Conditions
-----------------
Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1.old cerebral infarction (middle cerebral artery territory as documented on the T2 weight image [T2WI] of MRI) 2.between 6 months and 5 years of onset 3.National Institute of Health stroke scale (NIHSS) of between 9 and 20. Exclusion Criteria: 1.Seizure history 2. Pacemaker insertion

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Normal control<br> | |
| with Stem cell therapy plus G-CSF<br> | |
| G-CSF along<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
changes in cortical excitability in subjects with chronic stroke after stem cell therapy
Impact of the Implementation of a Referral Veno-venous Extracorporeal Membrane Oxygenation Centre on Mortality

Study Overview
=================
Brief Summary
-----------------
Current evidence suggest that regrouping patient supported by veno-venous ECMO in high-volume centre could improve outcome. A dedicated ECMO unit was implemented in Dijon. The objective of the present study was to evaluate the implementation of this unit. The hypothesis was that patient taken care within this structured care system would have lower mortality. This research comprises a retrospective observational study conducted in Dijon university hospital

Official Title
-----------------
Impact of the Implementation of a Referral Veno-venous Extracorporeal Membrane Oxygenation Centre on Mortality

Conditions
-----------------
Extracorporeal Membrane Oxygenation

Intervention / Treatment
-----------------
* Other: Collection of medical data


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient in an adult Dijon ICUs supported by veno-venous ECMO patient hospitalized between January the 1st 2011 and June the 30th 2021 Exclusion Criteria: Refusal to participate, patient admitted to pediatric ICU

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ECMO VV dedicated unit<br>Patient having benefited from an ECMO within the structured care unit | Other: Collection of medical data<br>* Collection of adverse events, of mortality, length of hospitalization<br>|
| ECMO VV without dedicated unit<br>Patient having benefited from an ECMO without the structured care unit | Other: Collection of medical data<br>* Collection of adverse events, of mortality, length of hospitalization<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality rate |  | 90 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of ECMO adverse events |  | through study completion, an average of 3 years | 
| Hospital length of stay |  | through study completion, an average of 3 years | 
| ICU length of stay |  | through study completion, an average of 3 years |
A Comparison of McGrath MAC®, Pentax-AWS® and Macintosh Direct Laryngoscopes for Nasotracheal Intubation

Study Overview
=================
Brief Summary
-----------------
A comparison of intubation time, difficulty of intubation in nasotracheal intubation using McGrath MAC®, Pentax-AWS® and Macintosh direct laryngoscopes

Detailed Description
-----------------
This trial is prospective randomized trial. The Objects are adult patients who need nasotracheal intubation for surgery. Using computed randomized table, participants are assigned to three groups, McGrath MAC®, Pentax-AWS® and Macintosh direct laryngoscopes. The intubation will be done by One expert anesthesiologist who have more than 10 years experience. Investigators compare intubation time, success rate and difficulty between three groups.

Official Title
-----------------
A Comparison of McGrath MAC®, Pentax-AWS® and Macintosh Direct Laryngoscopes for Nasotracheal Intubation

Conditions
-----------------
Intubation;Difficult

Intervention / Treatment
-----------------
* Device: McGrath
* Device: Pentax
* Device: Macintosh


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 19 years old ASA I or II Patients who need nasotracheal intubation for surgery Exclusion Criteria: Anatomical deformity in head and neck Modified Mallampati score IV Bleeding tendency in preoperative evaluation

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Macintosh<br>intubation using Macintosh direct laryngoscope | Device: Macintosh<br>* Macintosh direct laryngoscope<br>|
| Experimental: McGrath<br>intubation using McGrath MAC® | Device: McGrath<br>* McGrath videolaryngoscope<br>|
| Experimental: Pentax<br>intubation using Pentax-airway scope® | Device: Pentax<br>* Pentax videolaryngoscope<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intubation time | from endotracheal tube pass the nostril to end-tidal CO2 appear | within 5 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Success rate | Failure defined intubation time more than 120sec or SaO2 less than 95% | within 5 minutes |
The Effect of Beer, Red Wine and Fruit Juice on Blood Vessel Function in Persons With Cardiovascular Disease

Study Overview
=================
Brief Summary
-----------------
To study the effect of red wine, beer and fruit juice on endothelial function in patients with coronary Heart disease.

Official Title
-----------------
The Effect of Alcohol and Polyphenolic Compounds on Endothelial Function

Conditions
-----------------
Coronary Heart Disease

Intervention / Treatment
-----------------
* Behavioral: Moderate daily consumption of Red wine
* Behavioral: Moderate daily consumption of beer
* Behavioral: Moderate consumption of fruit juice rich in polyphenolics


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men or postmenopausal women with stable coronary heart disease Coronary heart disease should be verified by coronary angiography with at least 50% stenosis in at least one coronary vessel. Exclusion Criteria: Patients with myocardial infarction within the last tree months Persons with a present or earlier alcohol abuse Persons with a present or earlier drug abuse Person with malign disease Persons, that we consider unsuitable to carry through the examines.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Moderate daily consumption of Red wine|nan|
|Behavioral: Moderate daily consumption of beer|nan|
|Behavioral: Moderate consumption of fruit juice rich in polyphenolics|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in flow-mediated vasodilation after 2 weeks intervention compared with baseline |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lipid status after 2 weeks intervention compared with baseline |  |  | 
| Effects in Coagulation factors after 2 weeks intervention |  |  | 
| Effects on markers of inflammation after 2 weeks intervention |  |  | 
| Effects on markers of endothelial function after 2 weeks intervention |  |  | 
| Changes in the overall antioxidant activity in plasma after 2 weeks intervention |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Alcohol, Red wine, Endothelial function, Flow-mediated vasodilation, Cardiovascular disease
RSA-Study of Cemented Hip Prostheses With Five Different Articulations

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare wear and migration of the following hip prostheses: Charnley monoblock 22.2mm caput and OGEE polyethylene acetabular component Spectron EF stem with Reflection polyethylene cup and 28 mm CoCr caput Spectron EF stem with XLPE cup and 28 mm CoCr caput Spectron EF stem with Reflection polyethylene cup and 28 mm Oxinium caput Spectron EF stem with XLPE cup and 28 mm Oxinium caput

Detailed Description
-----------------
Detailed description in: Wear and migration of highly cross-linked and conventional cemented polyethylene cups with cobalt chrome or Oxinium femoral heads: a randomized radiostereometric study of 150 patients. Kadar T, Hallan G, Aamodt A, Indrekvam K, Badawy M, Skredderstuen A, Havelin LI, Stokke T, Haugan K, Espehaug B, Furnes O. J Orthop Res. 2011 Aug;29(8):1222-9. doi: 10.1002/jor.21389

Official Title
-----------------
A Prospective Randomized RSA-Study of Cemented Hip Prostheses With Five Different Articulations

Conditions
-----------------
Arthritis

Intervention / Treatment
-----------------
* Device: charnley OGEE
* Device: Spectron Reflection CoCr
* Device: Spectron XLPE CoCr
* Device: Spectron Reflection Oxinium
* Device: Spectron XLPE CoCR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: arthritis dysplasia Exclusion Criteria: obesitas charcots paget malignancy

Ages Eligible for Study
-----------------
Minimum Age: 59 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 2<br>articulation Spectron EF CoCr/ Reflection All-Poly Eto-sterilized | Device: Spectron Reflection CoCr<br>* Spectron Reflection CoCr<br>|
| Active Comparator: 3<br>articulation Spectron Ef CoCr/ Reflection All-Poly XLPE | Device: Spectron XLPE CoCr<br>* Spectron XLPE CoCr<br>|
| Active Comparator: 4<br>articulation Spectron EF Oxinium/ Reflection All-Poly Eto-sterilized | Device: Spectron Reflection Oxinium<br>* Spectron Reflection Oxinium<br>|
| Active Comparator: 5<br>articulation Spectron EF Oxinium/ Reflection XLPE | Device: Spectron XLPE CoCR<br>* Spectron XLPE CoCR<br>|
| Active Comparator: 1<br>articulation Charnley/ Ogee | Device: charnley OGEE<br>* charnley OGEE<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| wear |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| migration |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
RSA